Pfizer (NYSE: PFE) reported first-quarter 2026 revenue of $14.5 billion, representing 5% year-over-year growth, according to SEC 8-K filing.
📊 Stock Price at Article Time (May 6, 2026, 01:00 KST)
$26.12 ▼ -0.68%
₩38,449 (Exchange rate: 1,472)
Q1 Results at a Glance
Pfizer's first-quarter results surpassed market expectations. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 7% year-over-year. New product launches and acquired product portfolios drove 22% growth, supporting overall performance.
- Revenue: $14.451 billion, +5% YoY
- Reported EPS: $0.47, -10% vs. prior year ($0.52)
- Adjusted EPS: $0.75, -18% vs. prior year ($0.92)
- Reported Net Income: $2.687 billion, -9% YoY
- Adjusted Net Income: $4.29 billion, -18% YoY
2026 Full-Year Guidance
Pfizer maintained its 2026 full-year revenue guidance at $59.5–$62.5 billion. Adjusted EPS guidance remains unchanged at $2.80–$3.00. CFO David Denton stated: "We are pleased with Q1 commercial execution and operational efficiency, and we reaffirm our full-year guidance." CEO Albert Bourla added: "We believe Pfizer is well-positioned to lead in oncology and obesity treatment therapies."
- Full-year revenue guidance: $59.5–$62.5 billion
- Adjusted SG&A guidance: $12.5–$13.5 billion
- Adjusted R&D guidance: $10.5–$11.5 billion
- Adjusted effective tax rate: ~15.0%
- Adjusted EPS guidance: $2.80–$3.00
Market Reaction
Pfizer's stock traded at $26.12 (₩38,449) as of May 6 at 01:00 KST, down 0.68% from the prior session. Barron's noted that "Pfizer beat market expectations and is on a recovery path following the COVID-19 era." Biospace observed that "the unchanged full-year guidance somewhat offset the impact of Q1 beat expectations."
Business Segment Performance
Year-over-year revenue growth rates for key products are listed below. Specific dollar amounts for individual products were not disclosed in the filing.
- Global Biopharma segment revenue: $14.161 billion, +5% YoY (organic +2%)
- Pfizer CentreOne (contract manufacturing) segment revenue: $289 million, +6% YoY (organic +1%)
- Padcev (bladder cancer): +39% (organic basis)
- Eliquis (thromboembolism prevention): +8% (organic basis)
- Oncology biosimilars: +52% (organic basis)
- Nurtec ODT/Vydura (migraine): +41% (organic basis)
- Xeljanz (rare cardiac disease): +32% (organic basis)
- Vyndaqel family (rare cardiac disease): +4% (organic basis)
This article was auto-generated based on SEC 8-K filings and external news sources, with the objective of rapid dissemination of key data following the announcement. Investors are advised to review the company's official SEC filings before making trading decisions. Stock prices reflect the time of article publication and may differ from current levels.
